Fortunately, recent advancements in technology, like the introduction of computing using graphics processing units (GPUs), have made achieving microsecond (or even millisecond) long MD simulations fairly routine. Still, despite using longer timesteps and newer technologies, the utility of MD simulations in the drug discovery process has been hindered by MD's inability to adequately sample the conformational space. Often, MD simulations of a protein-ligand complex will see the ligand remain trapped in the binding mode the simulation had started in and will fail to capture any transition into alternative binding modes.